BACKGROUND: Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ(2) = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ(2) = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. CONCLUSIONS: Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia.
RCT Entities:
BACKGROUND: Differences among antipsychotics in terms of effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second generation antipsychotics (SGAs) are scarce. We aimed to compare the clinical effectiveness in the short-term of Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode schizophrenia-spectrum disorders. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. 202 first-episode drug-naïve patients were randomly assigned to Aripiprazole (N = 78), Ziprasidone (N = 62), or Quetiapine (N = 62) and followed-up for 3 months. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on intention-to-treat populations was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 months was small (13.86%). The treatment discontinuation rate differed significantly between treatment groups (Aripiprazole = 23.1%, Ziprasidone = 37.1% and Quetiapine = 61.3%) (χ(2) = 21.334; p < 0.001). Insufficient efficacy in the group of Quetiapine is the main reason for discontinuation rate differences (χ(2) = 20.223; p < 0.001). The mean time to all-cause discontinuation was significantly different between groups (LogRank = 23.467 p < 0.001). Aripiprazole and Quetiapine were associated with a greater depressive symptoms improvement (p = 0.043). The profile of side-effects varies between treatments. Patients on Quetiapine were less likely to be prescribed hypnotics. CONCLUSIONS:Patients treated with Quetiapine had a higher risk of treatment discontinuation in the short-term after a first episode due to insufficient efficacy. Establishing differences between SGAs may help clinicians in prescribing decisions for the treatment of individuals presenting with first-episode schizophrenia.
Authors: Joseph Ventura; Kenneth L Subotnik; Arielle Ered; Denise Gretchen-Doorly; Gerhard S Hellemann; Anja Vaskinn; Keith H Nuechterlein Journal: Schizophr Bull Date: 2014-02-21 Impact factor: 9.306
Authors: Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias Journal: Psychopharmacology (Berl) Date: 2014-01 Impact factor: 4.530
Authors: Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein Journal: Schizophr Res Date: 2014-12-08 Impact factor: 4.939
Authors: David D Kim; Alasdair M Barr; Lulu Lian; Jessica W Y Yuen; Diane Fredrikson; William G Honer; Allen E Thornton; Ric M Procyshyn Journal: NPJ Schizophr Date: 2021-05-25
Authors: Marcos Gómez-Revuelta; José María Pelayo-Terán; María Juncal-Ruiz; Víctor Ortiz-García de la Foz; Javier Vázquez-Bourgon; Ana González-Pinto; Benedicto Crespo-Facorro Journal: Int J Neuropsychopharmacol Date: 2018-12-01 Impact factor: 5.176
Authors: Tak Lam Lo; Matthew Warden; Yanling He; Tianmei Si; Seshadri Kalyanasundaram; Manickam Thirunavukarasu; Nurmiati Amir; Ahmad Hatim; Tomas Bautista; Cheng Lee; Robin Emsley; Jose Olivares; Yen Kuang Yang; Ronnachai Kongsakon; David Castle Journal: Asia Pac Psychiatry Date: 2016-06 Impact factor: 2.538